Expertise in
14
conditions

Dr. Evanthia C. Galanis

Oncology
MN - Cancer
200 1st St SW, 
Rochester, MN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
14
conditions
MN - Cancer
200 1st St SW, 
Rochester, MN 

Overview

Evanthia Galanis is an Oncologist practicing medicine in Rochester, Minnesota.

Dr. Galanis is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

She is actively involved in clinical research, co-authoring 149 peer reviewed articles and participating in 7 clinical trials. Dr. Galanis is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

MN - Cancer
200 1st St SW, Rochester, MN 55905

Additional Areas of Focus

Dr. Galanis has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Procedure, Other, Biological
Study Drug: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Study Phase: Phase 1/Phase 2
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2026
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: December 11, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Gemcitabine Hydrochloride, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug, Radiation
Study Drugs: Epacadostat, Bevacizumab
Study Phase: Phase 2
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Completed
Publish Date: January 02, 2020
Intervention Type: Other, Biological, Procedure
Study Phase: Phase 1
View 6 Less Clinical Trials

149 Total Publications

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 22, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-923-2592
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Ansell is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Ansell is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Ansell is currently accepting new patients.

Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-512-1667
Languages Spoken:
English, Filipino, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Go is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Go is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Rosai-Dorfman Disease, Histiocytosis, Reticulohistiocytoma, Bone Marrow Transplant, and Splenectomy. Dr. Go is currently accepting new patients.

Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Referral may be required

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-910-0296
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Francis Buadi is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Buadi is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, POEMS Syndrome, and Bone Marrow Transplant. Dr. Buadi is currently accepting new patients.

Frequently Asked Questions about Dr. Evanthia C. Galanis

How do I make an appointment with Dr. Evanthia C. Galanis?

You can book an appointment with Dr. Evanthia C. Galanis by calling their office at 507-512-1667. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Evanthia C. Galanis a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Evanthia C. Galanis is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Evanthia C. Galanis specialize in?

While Dr. Evanthia C. Galanis is a Oncology, they have specific expertise in Astrocytoma, Glioblastoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Evanthia C. Galanis participate in research or clinical trials?

Yes. Dr. Evanthia C. Galanis has published 149 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Evanthia C. Galanis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Evanthia C. Galanis accept my insurance?

Dr. Evanthia C. Galanis accepts most major insurance plans, including Anthem BCBS and Cambia Health Solutions. We recommend calling the office directly at 507-512-1667 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Galanis's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 59 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile